Host-Response Diagnostics: A Novel Validated Approach

We ‘read’ the immune system to characterize disease. The technique works by measuring the expression levels of numerous host immune genes, and then applying proprietary Inflammatix algorithms to produce rapid, clinically actionable results. Our efforts in developing diagnostic tests for acute infection and sepsis have been extensively validated and published in top-tier medical journals. Inflammatix is working with diagnostic instrument ‘platform’ partners to launch the HostDx™ Fever and HostDx™ Sepsis tests.

“The accurate and timely detection of sepsis remains a challenge … current methods of detection still rely on nonspecific clinical and laboratory signs.”

“Differentiating sepsis from non-infectious triggers of the systemic inflammatory response syndrome (SIRS) is difficult, especially in critically ill patients who may have SIRS for other reasons … It is perhaps unsurprising, therefore, that the search for a highly accurate biomarker of sepsis has become one of the holy grails of medicine.”

“New biomarkers will revolutionize the manner in which sepsis is managed, in terms of early recognition, targeting and titration of therapy, and prognostication. Point-of-care technologies will facilitate both measurement and patient management. It is also likely to benefit trial design and enable putative therapies to be better evaluated.”

Also covered by

Sign Up for updates: Find out the latest news.

Inflammatix is a molecular diagnostics company that is developing rapid tests that read the immune system to resolve major clinical and public health challenges. Our initial focus is on acute bacterial and viral infections, and sepsis